Clinical Features and Short-term Outcomes of 144 Patients With SARS in the Greater Toronto Area

CONTEXT: Severe acute respiratory syndrome (SARS) is an emerging infectious disease that first manifested in humans in China in November 2002 and has subsequently spread worldwide. OBJECTIVES: To describe the clinical characteristics and short-term outcomes of SARS in the first large group of patien...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JAMA : the journal of the American Medical Association 2003-06, Vol.289 (21), p.2801-2809
Hauptverfasser: Booth, Christopher M, Matukas, Larissa M, Tomlinson, George A, Rachlis, Anita R, Rose, David B, Dwosh, Hy A, Walmsley, Sharon L, Mazzulli, Tony, Avendano, Monica, Derkach, Peter, Ephtimios, Issa E, Kitai, Ian, Mederski, Barbara D, Shadowitz, Steven B, Gold, Wayne L, Hawryluck, Laura A, Rea, Elizabeth, Chenkin, Jordan S, Cescon, David W, Poutanen, Susan M, Detsky, Allan S
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2809
container_issue 21
container_start_page 2801
container_title JAMA : the journal of the American Medical Association
container_volume 289
creator Booth, Christopher M
Matukas, Larissa M
Tomlinson, George A
Rachlis, Anita R
Rose, David B
Dwosh, Hy A
Walmsley, Sharon L
Mazzulli, Tony
Avendano, Monica
Derkach, Peter
Ephtimios, Issa E
Kitai, Ian
Mederski, Barbara D
Shadowitz, Steven B
Gold, Wayne L
Hawryluck, Laura A
Rea, Elizabeth
Chenkin, Jordan S
Cescon, David W
Poutanen, Susan M
Detsky, Allan S
description CONTEXT: Severe acute respiratory syndrome (SARS) is an emerging infectious disease that first manifested in humans in China in November 2002 and has subsequently spread worldwide. OBJECTIVES: To describe the clinical characteristics and short-term outcomes of SARS in the first large group of patients in North America; to describe how these patients were treated and the variables associated with poor outcome. DESIGN, SETTING, AND PATIENTS: Retrospective case series involving 144 adult patients admitted to 10 academic and community hospitals in the greater Toronto, Ontario, area between March 7 and April 10, 2003, with a diagnosis of suspected or probable SARS. Patients were included if they had fever, a known exposure to SARS, and respiratory symptoms or infiltrates observed on chest radiograph. Patients were excluded if an alternative diagnosis was determined. MAIN OUTCOME MEASURES: Location of exposure to SARS; features of the history, physical examination, and laboratory tests at admission to the hospital; and 21-day outcomes such as death or intensive care unit (ICU) admission with or without mechanical ventilation. RESULTS: Of the 144 patients, 111 (77%) were exposed to SARS in the hospital setting. Features of the clinical examination most commonly found in these patients at admission were self-reported fever (99%), documented elevated temperature (85%), nonproductive cough (69%), myalgia (49%), and dyspnea (42%). Common laboratory features included elevated lactate dehydrogenase (87%), hypocalcemia (60%), and lymphopenia (54%). Only 2% of patients had rhinorrhea. A total of 126 patients (88%) were treated with ribavirin, although its use was associated with significant toxicity, including hemolysis (in 76%) and decrease in hemoglobin of 2 g/dL (in 49%). Twenty-nine patients (20%) were admitted to the ICU with or without mechanical ventilation, and 8 patients died (21-day mortality, 6.5%; 95% confidence interval [CI], 1.9%-11.8%). Multivariable analysis showed that the presence of diabetes (relative risk [RR], 3.1; 95% CI, 1.4-7.2; P = .01) or other comorbid conditions (RR, 2.5; 95% CI, 1.1-5.8; P = .03) were independently associated with poor outcome (death, ICU admission, or mechanical ventilation). CONCLUSIONS: The majority of cases in the SARS outbreak in the greater Toronto area were related to hospital exposure. In the event that contact history becomes unreliable, several features of the clinical presentation will be useful in raising the susp
doi_str_mv 10.1001/jama.289.21.joc30885
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_18017074</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><ama_id>196681</ama_id><sourcerecordid>345502511</sourcerecordid><originalsourceid>FETCH-LOGICAL-a415t-e852cfd092e902ee4c22a9f3889644a19622d822f0d7bdb54ef6e4ca4608b3323</originalsourceid><addsrcrecordid>eNpd0UFLwzAYBuAgipvTHyCIBEFvnfmSNE2OYzgVBhM38ViyNmUdbTOT9OC_N7LJwFxCkoeXjzcI3QAZAyHwuNWtHlOpxhTGW1swImV6goaQMpmwVMlTNCREySTjkg_QhfdbEhew7BwNgGaMA8-GKJ82dVcXusEzo0PvjMe6K_FyY11IgnEtXvShsG28txUGzvGbDrXpgsefddjg5eR9iesOh43Bzy5GGIdX1tkuWDyJ50t0VunGm6vDPkIfs6fV9CWZL55fp5N5ojmkITEypUVVEkWNItQYXlCqVcWkVIJzDUpQWkpKK1Jm63KdclOJiDQXRK4Zo2yEHva5O2e_euND3ta-ME2jO2N7n4MkkJGMR3j3D25t77o4W04BmIjVpRHdHlC_bk2Z71zdaved__UWwf0BaB_Lq5zuitofHZdCUPgNut67-FnHVyWEBPYDhPmD-w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>211363595</pqid></control><display><type>article</type><title>Clinical Features and Short-term Outcomes of 144 Patients With SARS in the Greater Toronto Area</title><source>MEDLINE</source><source>American Medical Association Journals</source><creator>Booth, Christopher M ; Matukas, Larissa M ; Tomlinson, George A ; Rachlis, Anita R ; Rose, David B ; Dwosh, Hy A ; Walmsley, Sharon L ; Mazzulli, Tony ; Avendano, Monica ; Derkach, Peter ; Ephtimios, Issa E ; Kitai, Ian ; Mederski, Barbara D ; Shadowitz, Steven B ; Gold, Wayne L ; Hawryluck, Laura A ; Rea, Elizabeth ; Chenkin, Jordan S ; Cescon, David W ; Poutanen, Susan M ; Detsky, Allan S</creator><creatorcontrib>Booth, Christopher M ; Matukas, Larissa M ; Tomlinson, George A ; Rachlis, Anita R ; Rose, David B ; Dwosh, Hy A ; Walmsley, Sharon L ; Mazzulli, Tony ; Avendano, Monica ; Derkach, Peter ; Ephtimios, Issa E ; Kitai, Ian ; Mederski, Barbara D ; Shadowitz, Steven B ; Gold, Wayne L ; Hawryluck, Laura A ; Rea, Elizabeth ; Chenkin, Jordan S ; Cescon, David W ; Poutanen, Susan M ; Detsky, Allan S</creatorcontrib><description>CONTEXT: Severe acute respiratory syndrome (SARS) is an emerging infectious disease that first manifested in humans in China in November 2002 and has subsequently spread worldwide. OBJECTIVES: To describe the clinical characteristics and short-term outcomes of SARS in the first large group of patients in North America; to describe how these patients were treated and the variables associated with poor outcome. DESIGN, SETTING, AND PATIENTS: Retrospective case series involving 144 adult patients admitted to 10 academic and community hospitals in the greater Toronto, Ontario, area between March 7 and April 10, 2003, with a diagnosis of suspected or probable SARS. Patients were included if they had fever, a known exposure to SARS, and respiratory symptoms or infiltrates observed on chest radiograph. Patients were excluded if an alternative diagnosis was determined. MAIN OUTCOME MEASURES: Location of exposure to SARS; features of the history, physical examination, and laboratory tests at admission to the hospital; and 21-day outcomes such as death or intensive care unit (ICU) admission with or without mechanical ventilation. RESULTS: Of the 144 patients, 111 (77%) were exposed to SARS in the hospital setting. Features of the clinical examination most commonly found in these patients at admission were self-reported fever (99%), documented elevated temperature (85%), nonproductive cough (69%), myalgia (49%), and dyspnea (42%). Common laboratory features included elevated lactate dehydrogenase (87%), hypocalcemia (60%), and lymphopenia (54%). Only 2% of patients had rhinorrhea. A total of 126 patients (88%) were treated with ribavirin, although its use was associated with significant toxicity, including hemolysis (in 76%) and decrease in hemoglobin of 2 g/dL (in 49%). Twenty-nine patients (20%) were admitted to the ICU with or without mechanical ventilation, and 8 patients died (21-day mortality, 6.5%; 95% confidence interval [CI], 1.9%-11.8%). Multivariable analysis showed that the presence of diabetes (relative risk [RR], 3.1; 95% CI, 1.4-7.2; P = .01) or other comorbid conditions (RR, 2.5; 95% CI, 1.1-5.8; P = .03) were independently associated with poor outcome (death, ICU admission, or mechanical ventilation). CONCLUSIONS: The majority of cases in the SARS outbreak in the greater Toronto area were related to hospital exposure. In the event that contact history becomes unreliable, several features of the clinical presentation will be useful in raising the suspicion of SARS. Although SARS is associated with significant morbidity and mortality, especially in patients with diabetes or other comorbid conditions, the vast majority (93.5%) of patients in our cohort survived.Published online May 6, 2003 (doi:10.1001/jama.289.21.JOC30885).</description><identifier>ISSN: 0098-7484</identifier><identifier>EISSN: 1538-3598</identifier><identifier>DOI: 10.1001/jama.289.21.joc30885</identifier><identifier>PMID: 12734147</identifier><identifier>CODEN: JAMAAP</identifier><language>eng</language><publisher>Chicago, IL: American Medical Association</publisher><subject>Adult ; Aged ; Anti-Inflammatory Agents - therapeutic use ; Antiviral Agents - adverse effects ; Antiviral Agents - therapeutic use ; Bacterial diseases ; Bacterial diseases of the respiratory system ; Biological and medical sciences ; Biomarkers - blood ; Communicable Diseases, Emerging - blood ; Communicable Diseases, Emerging - diagnosis ; Communicable Diseases, Emerging - epidemiology ; Communicable Diseases, Emerging - therapy ; Comorbidity ; Cough - etiology ; Demography ; Disease Outbreaks ; Disease Progression ; Dyspnea - etiology ; Female ; Fever - etiology ; Hospitalization ; Human bacterial diseases ; Humans ; Hydrocortisone - therapeutic use ; Infection Control ; Infectious diseases ; Intensive Care Units ; Lung - diagnostic imaging ; Male ; Medical sciences ; Middle Aged ; Ontario - epidemiology ; Patients ; Proportional Hazards Models ; Radiography ; Respiration, Artificial ; Retrospective Studies ; Ribavirin - adverse effects ; Ribavirin - therapeutic use ; SARS coronavirus ; SARS Virus - isolation &amp; purification ; Severe acute respiratory syndrome ; Severe Acute Respiratory Syndrome - blood ; Severe Acute Respiratory Syndrome - diagnosis ; Severe Acute Respiratory Syndrome - epidemiology ; Severe Acute Respiratory Syndrome - therapy ; Statistics, Nonparametric ; Survival Analysis</subject><ispartof>JAMA : the journal of the American Medical Association, 2003-06, Vol.289 (21), p.2801-2809</ispartof><rights>2003 INIST-CNRS</rights><rights>Copyright American Medical Association Jun 4, 2003</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a415t-e852cfd092e902ee4c22a9f3889644a19622d822f0d7bdb54ef6e4ca4608b3323</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://jamanetwork.com/journals/jama/articlepdf/10.1001/jama.289.21.joc30885$$EPDF$$P50$$Gama$$H</linktopdf><linktohtml>$$Uhttps://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.289.21.joc30885$$EHTML$$P50$$Gama$$H</linktohtml><link.rule.ids>64,314,777,781,3327,27905,27906,76238,76241</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=14866215$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12734147$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Booth, Christopher M</creatorcontrib><creatorcontrib>Matukas, Larissa M</creatorcontrib><creatorcontrib>Tomlinson, George A</creatorcontrib><creatorcontrib>Rachlis, Anita R</creatorcontrib><creatorcontrib>Rose, David B</creatorcontrib><creatorcontrib>Dwosh, Hy A</creatorcontrib><creatorcontrib>Walmsley, Sharon L</creatorcontrib><creatorcontrib>Mazzulli, Tony</creatorcontrib><creatorcontrib>Avendano, Monica</creatorcontrib><creatorcontrib>Derkach, Peter</creatorcontrib><creatorcontrib>Ephtimios, Issa E</creatorcontrib><creatorcontrib>Kitai, Ian</creatorcontrib><creatorcontrib>Mederski, Barbara D</creatorcontrib><creatorcontrib>Shadowitz, Steven B</creatorcontrib><creatorcontrib>Gold, Wayne L</creatorcontrib><creatorcontrib>Hawryluck, Laura A</creatorcontrib><creatorcontrib>Rea, Elizabeth</creatorcontrib><creatorcontrib>Chenkin, Jordan S</creatorcontrib><creatorcontrib>Cescon, David W</creatorcontrib><creatorcontrib>Poutanen, Susan M</creatorcontrib><creatorcontrib>Detsky, Allan S</creatorcontrib><title>Clinical Features and Short-term Outcomes of 144 Patients With SARS in the Greater Toronto Area</title><title>JAMA : the journal of the American Medical Association</title><addtitle>JAMA</addtitle><description>CONTEXT: Severe acute respiratory syndrome (SARS) is an emerging infectious disease that first manifested in humans in China in November 2002 and has subsequently spread worldwide. OBJECTIVES: To describe the clinical characteristics and short-term outcomes of SARS in the first large group of patients in North America; to describe how these patients were treated and the variables associated with poor outcome. DESIGN, SETTING, AND PATIENTS: Retrospective case series involving 144 adult patients admitted to 10 academic and community hospitals in the greater Toronto, Ontario, area between March 7 and April 10, 2003, with a diagnosis of suspected or probable SARS. Patients were included if they had fever, a known exposure to SARS, and respiratory symptoms or infiltrates observed on chest radiograph. Patients were excluded if an alternative diagnosis was determined. MAIN OUTCOME MEASURES: Location of exposure to SARS; features of the history, physical examination, and laboratory tests at admission to the hospital; and 21-day outcomes such as death or intensive care unit (ICU) admission with or without mechanical ventilation. RESULTS: Of the 144 patients, 111 (77%) were exposed to SARS in the hospital setting. Features of the clinical examination most commonly found in these patients at admission were self-reported fever (99%), documented elevated temperature (85%), nonproductive cough (69%), myalgia (49%), and dyspnea (42%). Common laboratory features included elevated lactate dehydrogenase (87%), hypocalcemia (60%), and lymphopenia (54%). Only 2% of patients had rhinorrhea. A total of 126 patients (88%) were treated with ribavirin, although its use was associated with significant toxicity, including hemolysis (in 76%) and decrease in hemoglobin of 2 g/dL (in 49%). Twenty-nine patients (20%) were admitted to the ICU with or without mechanical ventilation, and 8 patients died (21-day mortality, 6.5%; 95% confidence interval [CI], 1.9%-11.8%). Multivariable analysis showed that the presence of diabetes (relative risk [RR], 3.1; 95% CI, 1.4-7.2; P = .01) or other comorbid conditions (RR, 2.5; 95% CI, 1.1-5.8; P = .03) were independently associated with poor outcome (death, ICU admission, or mechanical ventilation). CONCLUSIONS: The majority of cases in the SARS outbreak in the greater Toronto area were related to hospital exposure. In the event that contact history becomes unreliable, several features of the clinical presentation will be useful in raising the suspicion of SARS. Although SARS is associated with significant morbidity and mortality, especially in patients with diabetes or other comorbid conditions, the vast majority (93.5%) of patients in our cohort survived.Published online May 6, 2003 (doi:10.1001/jama.289.21.JOC30885).</description><subject>Adult</subject><subject>Aged</subject><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Antiviral Agents - adverse effects</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Bacterial diseases</subject><subject>Bacterial diseases of the respiratory system</subject><subject>Biological and medical sciences</subject><subject>Biomarkers - blood</subject><subject>Communicable Diseases, Emerging - blood</subject><subject>Communicable Diseases, Emerging - diagnosis</subject><subject>Communicable Diseases, Emerging - epidemiology</subject><subject>Communicable Diseases, Emerging - therapy</subject><subject>Comorbidity</subject><subject>Cough - etiology</subject><subject>Demography</subject><subject>Disease Outbreaks</subject><subject>Disease Progression</subject><subject>Dyspnea - etiology</subject><subject>Female</subject><subject>Fever - etiology</subject><subject>Hospitalization</subject><subject>Human bacterial diseases</subject><subject>Humans</subject><subject>Hydrocortisone - therapeutic use</subject><subject>Infection Control</subject><subject>Infectious diseases</subject><subject>Intensive Care Units</subject><subject>Lung - diagnostic imaging</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Ontario - epidemiology</subject><subject>Patients</subject><subject>Proportional Hazards Models</subject><subject>Radiography</subject><subject>Respiration, Artificial</subject><subject>Retrospective Studies</subject><subject>Ribavirin - adverse effects</subject><subject>Ribavirin - therapeutic use</subject><subject>SARS coronavirus</subject><subject>SARS Virus - isolation &amp; purification</subject><subject>Severe acute respiratory syndrome</subject><subject>Severe Acute Respiratory Syndrome - blood</subject><subject>Severe Acute Respiratory Syndrome - diagnosis</subject><subject>Severe Acute Respiratory Syndrome - epidemiology</subject><subject>Severe Acute Respiratory Syndrome - therapy</subject><subject>Statistics, Nonparametric</subject><subject>Survival Analysis</subject><issn>0098-7484</issn><issn>1538-3598</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpd0UFLwzAYBuAgipvTHyCIBEFvnfmSNE2OYzgVBhM38ViyNmUdbTOT9OC_N7LJwFxCkoeXjzcI3QAZAyHwuNWtHlOpxhTGW1swImV6goaQMpmwVMlTNCREySTjkg_QhfdbEhew7BwNgGaMA8-GKJ82dVcXusEzo0PvjMe6K_FyY11IgnEtXvShsG28txUGzvGbDrXpgsefddjg5eR9iesOh43Bzy5GGIdX1tkuWDyJ50t0VunGm6vDPkIfs6fV9CWZL55fp5N5ojmkITEypUVVEkWNItQYXlCqVcWkVIJzDUpQWkpKK1Jm63KdclOJiDQXRK4Zo2yEHva5O2e_euND3ta-ME2jO2N7n4MkkJGMR3j3D25t77o4W04BmIjVpRHdHlC_bk2Z71zdaved__UWwf0BaB_Lq5zuitofHZdCUPgNut67-FnHVyWEBPYDhPmD-w</recordid><startdate>20030604</startdate><enddate>20030604</enddate><creator>Booth, Christopher M</creator><creator>Matukas, Larissa M</creator><creator>Tomlinson, George A</creator><creator>Rachlis, Anita R</creator><creator>Rose, David B</creator><creator>Dwosh, Hy A</creator><creator>Walmsley, Sharon L</creator><creator>Mazzulli, Tony</creator><creator>Avendano, Monica</creator><creator>Derkach, Peter</creator><creator>Ephtimios, Issa E</creator><creator>Kitai, Ian</creator><creator>Mederski, Barbara D</creator><creator>Shadowitz, Steven B</creator><creator>Gold, Wayne L</creator><creator>Hawryluck, Laura A</creator><creator>Rea, Elizabeth</creator><creator>Chenkin, Jordan S</creator><creator>Cescon, David W</creator><creator>Poutanen, Susan M</creator><creator>Detsky, Allan S</creator><general>American Medical Association</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7QL</scope><scope>7QP</scope><scope>7TK</scope><scope>7TS</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>RC3</scope></search><sort><creationdate>20030604</creationdate><title>Clinical Features and Short-term Outcomes of 144 Patients With SARS in the Greater Toronto Area</title><author>Booth, Christopher M ; Matukas, Larissa M ; Tomlinson, George A ; Rachlis, Anita R ; Rose, David B ; Dwosh, Hy A ; Walmsley, Sharon L ; Mazzulli, Tony ; Avendano, Monica ; Derkach, Peter ; Ephtimios, Issa E ; Kitai, Ian ; Mederski, Barbara D ; Shadowitz, Steven B ; Gold, Wayne L ; Hawryluck, Laura A ; Rea, Elizabeth ; Chenkin, Jordan S ; Cescon, David W ; Poutanen, Susan M ; Detsky, Allan S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a415t-e852cfd092e902ee4c22a9f3889644a19622d822f0d7bdb54ef6e4ca4608b3323</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Antiviral Agents - adverse effects</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Bacterial diseases</topic><topic>Bacterial diseases of the respiratory system</topic><topic>Biological and medical sciences</topic><topic>Biomarkers - blood</topic><topic>Communicable Diseases, Emerging - blood</topic><topic>Communicable Diseases, Emerging - diagnosis</topic><topic>Communicable Diseases, Emerging - epidemiology</topic><topic>Communicable Diseases, Emerging - therapy</topic><topic>Comorbidity</topic><topic>Cough - etiology</topic><topic>Demography</topic><topic>Disease Outbreaks</topic><topic>Disease Progression</topic><topic>Dyspnea - etiology</topic><topic>Female</topic><topic>Fever - etiology</topic><topic>Hospitalization</topic><topic>Human bacterial diseases</topic><topic>Humans</topic><topic>Hydrocortisone - therapeutic use</topic><topic>Infection Control</topic><topic>Infectious diseases</topic><topic>Intensive Care Units</topic><topic>Lung - diagnostic imaging</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Ontario - epidemiology</topic><topic>Patients</topic><topic>Proportional Hazards Models</topic><topic>Radiography</topic><topic>Respiration, Artificial</topic><topic>Retrospective Studies</topic><topic>Ribavirin - adverse effects</topic><topic>Ribavirin - therapeutic use</topic><topic>SARS coronavirus</topic><topic>SARS Virus - isolation &amp; purification</topic><topic>Severe acute respiratory syndrome</topic><topic>Severe Acute Respiratory Syndrome - blood</topic><topic>Severe Acute Respiratory Syndrome - diagnosis</topic><topic>Severe Acute Respiratory Syndrome - epidemiology</topic><topic>Severe Acute Respiratory Syndrome - therapy</topic><topic>Statistics, Nonparametric</topic><topic>Survival Analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Booth, Christopher M</creatorcontrib><creatorcontrib>Matukas, Larissa M</creatorcontrib><creatorcontrib>Tomlinson, George A</creatorcontrib><creatorcontrib>Rachlis, Anita R</creatorcontrib><creatorcontrib>Rose, David B</creatorcontrib><creatorcontrib>Dwosh, Hy A</creatorcontrib><creatorcontrib>Walmsley, Sharon L</creatorcontrib><creatorcontrib>Mazzulli, Tony</creatorcontrib><creatorcontrib>Avendano, Monica</creatorcontrib><creatorcontrib>Derkach, Peter</creatorcontrib><creatorcontrib>Ephtimios, Issa E</creatorcontrib><creatorcontrib>Kitai, Ian</creatorcontrib><creatorcontrib>Mederski, Barbara D</creatorcontrib><creatorcontrib>Shadowitz, Steven B</creatorcontrib><creatorcontrib>Gold, Wayne L</creatorcontrib><creatorcontrib>Hawryluck, Laura A</creatorcontrib><creatorcontrib>Rea, Elizabeth</creatorcontrib><creatorcontrib>Chenkin, Jordan S</creatorcontrib><creatorcontrib>Cescon, David W</creatorcontrib><creatorcontrib>Poutanen, Susan M</creatorcontrib><creatorcontrib>Detsky, Allan S</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Physical Education Index</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>JAMA : the journal of the American Medical Association</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Booth, Christopher M</au><au>Matukas, Larissa M</au><au>Tomlinson, George A</au><au>Rachlis, Anita R</au><au>Rose, David B</au><au>Dwosh, Hy A</au><au>Walmsley, Sharon L</au><au>Mazzulli, Tony</au><au>Avendano, Monica</au><au>Derkach, Peter</au><au>Ephtimios, Issa E</au><au>Kitai, Ian</au><au>Mederski, Barbara D</au><au>Shadowitz, Steven B</au><au>Gold, Wayne L</au><au>Hawryluck, Laura A</au><au>Rea, Elizabeth</au><au>Chenkin, Jordan S</au><au>Cescon, David W</au><au>Poutanen, Susan M</au><au>Detsky, Allan S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical Features and Short-term Outcomes of 144 Patients With SARS in the Greater Toronto Area</atitle><jtitle>JAMA : the journal of the American Medical Association</jtitle><addtitle>JAMA</addtitle><date>2003-06-04</date><risdate>2003</risdate><volume>289</volume><issue>21</issue><spage>2801</spage><epage>2809</epage><pages>2801-2809</pages><issn>0098-7484</issn><eissn>1538-3598</eissn><coden>JAMAAP</coden><abstract>CONTEXT: Severe acute respiratory syndrome (SARS) is an emerging infectious disease that first manifested in humans in China in November 2002 and has subsequently spread worldwide. OBJECTIVES: To describe the clinical characteristics and short-term outcomes of SARS in the first large group of patients in North America; to describe how these patients were treated and the variables associated with poor outcome. DESIGN, SETTING, AND PATIENTS: Retrospective case series involving 144 adult patients admitted to 10 academic and community hospitals in the greater Toronto, Ontario, area between March 7 and April 10, 2003, with a diagnosis of suspected or probable SARS. Patients were included if they had fever, a known exposure to SARS, and respiratory symptoms or infiltrates observed on chest radiograph. Patients were excluded if an alternative diagnosis was determined. MAIN OUTCOME MEASURES: Location of exposure to SARS; features of the history, physical examination, and laboratory tests at admission to the hospital; and 21-day outcomes such as death or intensive care unit (ICU) admission with or without mechanical ventilation. RESULTS: Of the 144 patients, 111 (77%) were exposed to SARS in the hospital setting. Features of the clinical examination most commonly found in these patients at admission were self-reported fever (99%), documented elevated temperature (85%), nonproductive cough (69%), myalgia (49%), and dyspnea (42%). Common laboratory features included elevated lactate dehydrogenase (87%), hypocalcemia (60%), and lymphopenia (54%). Only 2% of patients had rhinorrhea. A total of 126 patients (88%) were treated with ribavirin, although its use was associated with significant toxicity, including hemolysis (in 76%) and decrease in hemoglobin of 2 g/dL (in 49%). Twenty-nine patients (20%) were admitted to the ICU with or without mechanical ventilation, and 8 patients died (21-day mortality, 6.5%; 95% confidence interval [CI], 1.9%-11.8%). Multivariable analysis showed that the presence of diabetes (relative risk [RR], 3.1; 95% CI, 1.4-7.2; P = .01) or other comorbid conditions (RR, 2.5; 95% CI, 1.1-5.8; P = .03) were independently associated with poor outcome (death, ICU admission, or mechanical ventilation). CONCLUSIONS: The majority of cases in the SARS outbreak in the greater Toronto area were related to hospital exposure. In the event that contact history becomes unreliable, several features of the clinical presentation will be useful in raising the suspicion of SARS. Although SARS is associated with significant morbidity and mortality, especially in patients with diabetes or other comorbid conditions, the vast majority (93.5%) of patients in our cohort survived.Published online May 6, 2003 (doi:10.1001/jama.289.21.JOC30885).</abstract><cop>Chicago, IL</cop><pub>American Medical Association</pub><pmid>12734147</pmid><doi>10.1001/jama.289.21.joc30885</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0098-7484
ispartof JAMA : the journal of the American Medical Association, 2003-06, Vol.289 (21), p.2801-2809
issn 0098-7484
1538-3598
language eng
recordid cdi_proquest_miscellaneous_18017074
source MEDLINE; American Medical Association Journals
subjects Adult
Aged
Anti-Inflammatory Agents - therapeutic use
Antiviral Agents - adverse effects
Antiviral Agents - therapeutic use
Bacterial diseases
Bacterial diseases of the respiratory system
Biological and medical sciences
Biomarkers - blood
Communicable Diseases, Emerging - blood
Communicable Diseases, Emerging - diagnosis
Communicable Diseases, Emerging - epidemiology
Communicable Diseases, Emerging - therapy
Comorbidity
Cough - etiology
Demography
Disease Outbreaks
Disease Progression
Dyspnea - etiology
Female
Fever - etiology
Hospitalization
Human bacterial diseases
Humans
Hydrocortisone - therapeutic use
Infection Control
Infectious diseases
Intensive Care Units
Lung - diagnostic imaging
Male
Medical sciences
Middle Aged
Ontario - epidemiology
Patients
Proportional Hazards Models
Radiography
Respiration, Artificial
Retrospective Studies
Ribavirin - adverse effects
Ribavirin - therapeutic use
SARS coronavirus
SARS Virus - isolation & purification
Severe acute respiratory syndrome
Severe Acute Respiratory Syndrome - blood
Severe Acute Respiratory Syndrome - diagnosis
Severe Acute Respiratory Syndrome - epidemiology
Severe Acute Respiratory Syndrome - therapy
Statistics, Nonparametric
Survival Analysis
title Clinical Features and Short-term Outcomes of 144 Patients With SARS in the Greater Toronto Area
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T17%3A00%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20Features%20and%20Short-term%20Outcomes%20of%20144%20Patients%20With%20SARS%20in%20the%20Greater%20Toronto%20Area&rft.jtitle=JAMA%20:%20the%20journal%20of%20the%20American%20Medical%20Association&rft.au=Booth,%20Christopher%20M&rft.date=2003-06-04&rft.volume=289&rft.issue=21&rft.spage=2801&rft.epage=2809&rft.pages=2801-2809&rft.issn=0098-7484&rft.eissn=1538-3598&rft.coden=JAMAAP&rft_id=info:doi/10.1001/jama.289.21.joc30885&rft_dat=%3Cproquest_pubme%3E345502511%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=211363595&rft_id=info:pmid/12734147&rft_ama_id=196681&rfr_iscdi=true